ALLERGAN CREAM 30G 2G/100G

ALLERGAN 2G/100 G CREMA

active ingredients

100g of cream contain: Active ingredient: Defenhydramine hydrochloride g. 2 Excipients with known effect: lanolin, p-hydroxybenzoate methyl (E218), p-hydroxybenzoate propile (E216). For excipients see 6.1.

Excellent

Stearic acid, glycerin, lanolin, triethanolamine, p-hydroxybenzoate (E218), p-hydroxybenzoate propel (E216), distilled water.

Therapeutic indications

Local symptomatic treatment of pruriginous dermatitis, solar erythema, insect bites.

Contraindications

Hypersensitivity known to components and other antihistamines of similar chemical structure. Children under 2 years.

Population

Spread a thin layer on the affected part, 2 or 3 times a day. Do not exceed the recommended doses.

Conservation

None.

Warnings

Do not use with occlusive bandage. The use of the product, especially if prolonged, may give rise to sensitization phenomena; where this occurs interrupt treatment and consult your doctor. Apply cream on reduced skin areas. ALLERGAN Cream should not be applied on skin areas with bladders, on living sores and scarring surfaces. Avoid contact with eyes or other mucous membranes. In the case of solar erythema do not expose the skin to the sun. If after a short period of treatment there was no improvement or if skin rashes, irritation and burning, suspend treatment and address to the doctor. Do not use the medicine after the expiry date indicated on the package. Keep the medicine out of reach of children. Important information about some excipients This medicine contains: • lanolin: it can cause local skin reactions (e.g. contact dermatitis). • P-hydroxybenzoate methyl (E218) and p-hydroxybenzoate propile (E216): may cause allergic reactions (also delayed).

Interactions

No notes.

Effects

Burning, rashes, photosensitivity reactions were found. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse

Overdosing

Not reported hyperdose phenomena. Eventually, adopt symptomatic therapy.

In pregnant women and during breastfeeding the product should only be used in case of actual need and under the direct control of the doctor.

Source: Farmadati